A plan to slash drug review times at the Food and Drug Administration is sparking deep concerns among agency staffers and ...
In four months, the program, which aims to modernize how the FDA reviews imported products, increased processing speed by 66% ...
Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...
Stocktwits on MSN
Disc Medicine, Sanofi, Eli Lilly shares slip on reports of FDA increasing review time for drugs granted priority review vouchers
FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10 ...
A key element of the law is the establishment of a system to trace food, which is key to reducing the severity of foodborne illness outbreaks.
MedPage Today on MSN
FDA has taken cautious approach with mifepristone, review suggests
Abortion drug has long been deemed safe based on scientific evidence, researchers say ...
Pro-life advocates are calling for action as top federal health officials deny reports that they are delaying a promised safety review of the abortion pill. The Food and Drug Administration (FDA), an ...
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in ...
Optum notable drugs nearing FDA approval include Anaphylm, Sotyktu, and insulin icodec with decisions expected early 2026.
The Food and Drug Administration (FDA) defied the advice of its own drug safety experts to warn pregnant women about Tylenol for nearly a decade, internal reports and presentations obtained by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results